Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer

Clinical Cancer Research

Volumn 20, Issue 23, 2014, Pages 5995-6005

  Brown, Jason R ^a   Wimberly, Hallie ^a   Lannin, Donald R ^a   Nixon, Christian ^a   Rimm, David L ^a   Bossuyt, Veerle ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CARBOPLATIN; CD20 ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ETOPOSIDE; KI 67 ANTIGEN; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; AGE; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SIZE; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FLOW CYTOMETRY; HUMAN; IMMUNOFLUORESCENCE TEST; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; PATHOLOGIST; PREDICTION; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; REPRODUCIBILITY; SCORING SYSTEM; STROMA; TONSIL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; UNIVARIATE ANALYSIS; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; BREAST NEOPLASMS; CANCER GRADING; FEMALE; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD20; ANTIGENS, CD3; ANTIGENS, CD8; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84918591788     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1622     Document Type: Article

References (38)

1. Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer 2004;100:2512-32.
2. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
3. Cleator SJ, Makris A, Ashley SE, Lal R, Powles TJ. Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol 2005;16:267-72.
4. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006;24:1940-9.
5. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-85.
6. Gutkin DW. Tumor infiltration by immune cells. In: Shurin MR, Umansky V, Malyguine A, editors. The tumor immunoenvironment. New York, NY: Springer Science; 2013.
7. Ryan G. T-cell signalling: CD3 conformation is crucial for signalling. Nat Rev Immunol 2010;10:7.
8. + lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011;29:1949-55.
9. Leong PP, Mohammad R, Ibrahim N, Ithnin H, Abdullah M, Davis WC, et al. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol Lett 2006;102:229-36.
10. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994;15:450-4.
11. + B cells: the other tumor-infiltrating lymphocytes. J Immunol 2010;185:4977-82.
12. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A 2012;109:2796-801.
13. Hornychova H, Melichar B, Tomsova M, Mergancova J, Urminska H, Ryska A. Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest 2008;26:1024-31.
14. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28:105-13.
15. Lee HJ, Seo JY, Ahn JH, Ahn SH, Gong G. Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer 2013;16:32-9.
16. Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat 2012;132:793-805.
17. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 2011;13:R126.
18. + lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 2013;109:2705-13.
19. Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012;10:205.
20. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 2012;132:545-53.
21. Klintrup K, Makinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005;41:2645-54.
22. Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rebe C, et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 2011;224:389-400.
23. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013;31:860-7.
24. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
25. + cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 2009;10:877-84.
26. Halama N, Zoernig I, Spille A, Westphal K, Schirmacher P, Jaeger D, et al. Estimation of immune cell densities in immune cell conglomerates: an approach for high-throughput quantification. PLoS ONE 2009;4:e7847.
27. Loughlin PM, Cooke TG, George WD, Gray AJ, Stott DI, Going JJ. Quantifying tumour-infiltrating lymphocyte subsets: a practical immuno-histochemical method. J Immunol Methods 2007;321:32-40.
28. Allard MA, Bachet JB, Beauchet A, Julie C, Malafosse R, Penna C, et al. Linear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor. Diagn Pathol 2012;7:156.
29. Brown JR, Digiovanna MP, Killelea B, Lannin DR, Rimm DL. Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer. Lab Invest 2014;94:98-106.
30. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-7.
31. Dolled-Filhart M, Gustavson M, Camp RL, Rimm DL, Tonkinson JL, Christiansen J. Automated analysis of tissue microarrays. Methods Mol Biol 2010;664:151-62.
32. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for join-point regression with applications to cancer rates. Stat Med 2000;19:335-51.
33. Hannani D, Locher C, Yamazaki T, Colin-Minard V, Vetizou M, Aymeric L, et al. Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. Cell Death Differ 2014;21:50-8.
34. Janols H, Bredberg A, Thuvesson I, Janciauskiene S, Grip O, Wullt M. Lymphocyte and monocyte flow cytometry immunophenotyping as a diagnostic tool in uncharacteristic inflammatory disorders. BMC Infect Dis 2010;10:205.
35. Zaritskaya L, Shurin MR, Sayers TJ, Malyguine AM. New flow cytometric assays for monitoring cell-mediated cytotoxicity. Expert Rev Vaccines 2010;9:601-16.
36. Abuzakouk M, Feighery C, O'Farrelly C. Collagenase and Dispase enzymes disrupt lymphocyte surface molecules. J Immunol Methods 1996;194:211-6.
37. Robins HS, Ericson NG, Guenthoer J, O'Briant KC, Tewari M, Drescher CW, et al. Digital genomic quantification of tumor-infiltrating lymphocytes. Sci Transl Med 2013;5:214ra169.
38. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. Harmonization of the evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs-working group 2014. Ann Oncol. 2014 Sep 11. [Epub ahead of print].